# Plain Language Summary: Improved Transparency of Foreign Drug Manufacturing Act of 2022

Right now, when pharmaceutical companies make drugs overseas and ship them to the United States, there's a gap in what the government knows about where and how those drugs are actually being made. This bill closes that gap by requiring foreign drug manufacturers to register with the FDA and report detailed information about their operations, just like domestic manufacturers already do.

Here's what changes: If a foreign company makes any part of a drug that will be sold in America—including the active ingredient (the part that actually does the medical work)—they now have to tell the FDA about it. Companies that import these drugs also have to certify that they've found every single place where their drug is being manufactured and have notified each of those foreign facilities about their legal obligation to register. This means the FDA gets a complete picture of the entire supply chain instead of just knowing about the final step before import.

The bill also requires these foreign manufacturers to report their production numbers more frequently. Instead of reporting once a year, they'll now report four times a year—in March, June, September, and December. This gives the FDA much more current information about how much of each drug is being produced and helps them spot potential problems faster, like if a facility suddenly stops producing a medication or if there's a shortage developing.

The practical effect is that the government will have better visibility into where America's medicines come from and who's making them. This could help the FDA respond faster to safety issues, prevent counterfeit drugs from entering the supply chain, and ensure that foreign manufacturers meet the same accountability standards as American ones.

Improved Transparency of Foreign Drug Manufacturing Act of 2022

Eshoo, Anna G.

Improved Transparency of Foreign Drug Manufacturing Act of 2022 This bill modifies requirements for certain foreign establishments that manufacture drugs (including active pharmaceutical ingredients) to register with the Food and Drug Administration (FDA). Under this bill, if an establishment outside of the United States manufactures (or otherwise processes or prepares) a drug to be imported (or offered for import) into the United States, the establishment must comply with the registration requirements even if the drug undergoes further manufacturing at another non-U.S. establishment prior to importation into the United States. A non-U.S. manufacturing establishment must also file with the FDA a list of drugs manufactured by the establishment. For each drug on the list, the establishment must (1) identify every other known establishment where additional manufacturing is performed, and (2) notify each foreign establishment involved of the listing of the drug and the obligation to register with the FDA. The bill also requires each registered non-U.S. manufacturing establishment to report every three months to the FDA a list of each drug it manufactures for commercial distribution, where currently this report is required once a year.